Firms Partnered to Expand Prostate Cancer Imaging
Profound Medical and Telix Pharmaceuticals have joined forces to improve how physicians select patients for focal therapy.
Updated on Oct. 10, 2026 in Men’s Health
Live Poll
Do you trust that medical technology partnerships provide more personalized treatment options for patients?
Profound Medical and Telix Pharmaceuticals entered a co-education agreement to help physicians better understand the use of PSMA-PET imaging alongside TULSA-PRO prostate ablation technology. This collaboration aims to improve patient selection pathways for men with prostate cancer.
Why it matters
Enhanced coordination between advanced imaging and ablation therapies helps physicians identify which prostate cancer patients are candidates for focal treatment. This initiative focuses on educating specialists on how to better utilize these diagnostic and therapeutic tools together.
Prostate cancer morphology distribution shows that 85% of cases are multifocal, compared to 15% that are unifocal, which informs the 15-25% of the patient population considered for focal ablation. Future software integration capabilities remain under development.
The players
Profound Medical
A medical technology company headquartered in Toronto that develops MRI-guided prostate ablation systems.
Telix Pharmaceuticals
A biopharmaceutical company headquartered in Melbourne, Australia, that specializes in molecular imaging and PSMA-PET technologies.
The details
Telix Pharmaceuticals provides PSMA-PET molecular imaging that identifies the location of cancer cells, while Profound Medical offers MRI-guided TULSA-PRO technology to ablate prostate tissue. By combining these, the companies aim to help physicians visualize cancer spread to guide precision ablation. The partnership will roll out educational webinars and clinical case study programs for urologists, radiologists, and nuclear medicine physicians.
Timeline
October 9, 2026: Profound and Telix announced their co-education agreement.
Health Landscape
This partnership reflects a broader trend of integrating molecular diagnostic precision with minimally invasive surgical techniques in oncology. It marks a departure from silos between imaging and therapy to support more tailored, focal ablation approaches for prostate cancer patients.
If you are considering prostate cancer treatment, ask your doctor if your diagnosis is unifocal or multifocal, as this impacts your eligibility for different therapy types. You may want to discuss with your urologist whether advanced imaging options, such as PSMA-PET, are appropriate for your care plan.
The takeaway
Advancements in imaging continue to refine how clinicians distinguish between localized and widespread disease in the prostate. Focus on tracking your specific diagnosis profile and having a detailed conversation with your physician about the best treatment pathway for your unique needs.
Further reading
Learn more about advancements in diagnostic technology at Men’s Health.
Live Poll
Do you trust that medical technology partnerships provide more personalized treatment options for patients?
